Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions
Anticipating annual pricing of up to $10,000 per patient for PCSK9 cholesterol-lowering drugs that will be prescribed for life, payers are taking a very close look at how to limit use to the patients who most need to take the drugs in the new class instead of low-cost statins.
You may also be interested in...
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
Alliance for Aging Research worries the studies could drag on as long as the nine years Biogen is allowed for collecting Phase IV clinical data on its Aduhelm.
US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.